Christel Mertens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christel Mertens has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Didier Gaston Ebo
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
48 shared publications - Vito Sabato
Department of Immunology, Allergology, Rheumatology, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
33 shared publications - Jessy Elst
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
32 shared publications - Margo Maria Hagendorens
Immunology–Allergology–Rheumatology, Faculty of Medicine and Health Sciences Antwerp University, Hospital, Infla‐Med Centre of Excellence, Antwerp University, University of Antwerp Antwerp Belgium
28 shared publications - Athina Ludovica Van Gasse
Department of Pediatrics, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
18 shared publications - Margaretha Antje Faber
Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and Infla-Med Centre of Excellence, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
16 shared publications
Latest Publications
Non‐Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation
Flow cytometric analysis of activated basophils, known as the basophil activation test (BAT), is a tool available for the diagnosis of IgE‐mediated allergic reactions. Despite its reported clinical utility, around 10%–20% of tested subjects fall into the category of basophil non‐releasers, meaning that their basophils fail to degranulate upon IgE‐mediated stimulation in vitro. Several factors causing this non‐releaser status have been identified, but we currently lack a unified nomenclature to define such inconclusive BAT results and the practical steps to minimize such outcomes. In accordance with the STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement, non‐releasers must be reported and considered in the calculation of clinical BAT performance metrics, as failure to do so significantly limits the broader implementation of BAT in routine practice. This review provides an overview of intrinsic and extrinsic factors responsible for the basophil non‐releaser phenotype in BAT. Furthermore, it proposes a standardized nomenclature for consistently reporting and integrating inconclusive BAT results in the diagnostic performance metrics and suggests diagnostic algorithms to facilitate their interpretation in clinical practice.
Non‐Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation
Flow cytometric analysis of activated basophils, known as the basophil activation test (BAT), is a tool available for the diagnosis of IgE‐mediated allergic reactions. Despite its reported clinical utility, around 10%–20% of tested subjects fall into the category of basophil non‐releasers, meaning that their basophils fail to degranulate upon IgE‐mediated stimulation in vitro. Several factors causing this non‐releaser status have been identified, but we currently lack a unified nomenclature to define such inconclusive BAT results and the practical steps to minimize such outcomes. In accordance with the STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement, non‐releasers must be reported and considered in the calculation of clinical BAT performance metrics, as failure to do so significantly limits the broader implementation of BAT in routine practice. This review provides an overview of intrinsic and extrinsic factors responsible for the basophil non‐releaser phenotype in BAT. Furthermore, it proposes a standardized nomenclature for consistently reporting and integrating inconclusive BAT results in the diagnostic performance metrics and suggests diagnostic algorithms to facilitate their interpretation in clinical practice.
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
- 5 November 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 65 (2)
L’allergie au cannabis et les syndromes de réactivité croisée : une feuille de route pour un diagnostic et une prise en charge corrects
- 5 November 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 65 (2)
L’allergie au cannabis et les syndromes de réactivité croisée : une feuille de route pour un diagnostic et une prise en charge corrects
- 11 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (764) , eado4463
Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models
Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in rare cases, anaphylaxis. Both adverse reactions vary between types of NMBAs, with rocuronium, a widely used nondepolarizing NMBA, inducing one of the longest rNMB durations and highest anaphylaxis incidences. rNMB induced by rocuronium can be reversed by the synthetic γ-cyclodextrin sugammadex. However, in rare cases, sugammadex can provoke anaphylaxis. Thus, additional therapeutic options are needed. Rocuronium-induced anaphylaxis is proposed to rely on preexisting rocuronium-binding antibodies. To understand the pathogenesis of rocuronium-induced anaphylaxis and to identify potential therapeutics, we investigated the memory B cell antibody repertoire of patients with suspected hypersensitivity to rocuronium. We identified polyclonal antibody repertoires with a high diversity among V(D)J genes without evidence of clonal groups. When recombinantly expressed, these antibodies demonstrated specificity and low affinity for rocuronium without cross-reactivity for other NMBAs. Moreover, when these antibodies were expressed as human immunoglobulin E (IgE), they triggered human mast cell activation and passive systemic anaphylaxis in transgenic mice, although their affinities were insufficient to serve as reversal agents. Rocuronium-specific, high-affinity antibodies were thus isolated from rocuronium-immunized mice. The highest-affinity antibody was able to reverse rocuronium-induced neuromuscular blockade in nonhuman primates with kinetics comparable to that of sugammadex. Together, these data support the hypothesis that antibodies cause anaphylactic reactions to rocuronium and pave the way for improved diagnostics and neuromuscular blockade reversal agents.
- 11 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (764) , eado4463
Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models
Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in rare cases, anaphylaxis. Both adverse reactions vary between types of NMBAs, with rocuronium, a widely used nondepolarizing NMBA, inducing one of the longest rNMB durations and highest anaphylaxis incidences. rNMB induced by rocuronium can be reversed by the synthetic γ-cyclodextrin sugammadex. However, in rare cases, sugammadex can provoke anaphylaxis. Thus, additional therapeutic options are needed. Rocuronium-induced anaphylaxis is proposed to rely on preexisting rocuronium-binding antibodies. To understand the pathogenesis of rocuronium-induced anaphylaxis and to identify potential therapeutics, we investigated the memory B cell antibody repertoire of patients with suspected hypersensitivity to rocuronium. We identified polyclonal antibody repertoires with a high diversity among V(D)J genes without evidence of clonal groups. When recombinantly expressed, these antibodies demonstrated specificity and low affinity for rocuronium without cross-reactivity for other NMBAs. Moreover, when these antibodies were expressed as human immunoglobulin E (IgE), they triggered human mast cell activation and passive systemic anaphylaxis in transgenic mice, although their affinities were insufficient to serve as reversal agents. Rocuronium-specific, high-affinity antibodies were thus isolated from rocuronium-immunized mice. The highest-affinity antibody was able to reverse rocuronium-induced neuromuscular blockade in nonhuman primates with kinetics comparable to that of sugammadex. Together, these data support the hypothesis that antibodies cause anaphylactic reactions to rocuronium and pave the way for improved diagnostics and neuromuscular blockade reversal agents.
- 23 August 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 915-917
Morphine-specific IgE testing in the diagnosis of neuromuscular blocking agent allergy: proper use and interpretation
- 23 August 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 915-917
Morphine-specific IgE testing in the diagnosis of neuromuscular blocking agent allergy: proper use and interpretation
- 9 July 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 64 (5)
Propriétés allergiques et activatrices de MRGPRX2 des médicaments : vers un algorithme mécanistique résolutif
- 9 July 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 64 (5)
Propriétés allergiques et activatrices de MRGPRX2 des médicaments : vers un algorithme mécanistique résolutif
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status